Navigation Links
Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
Date:11/15/2013

Arnhem, The Netherlands - An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.

"Quantitative models predicting the risk of acute (and late) genito-urinary (GU) toxicity in patients treated with high dose radiotherapy for prostate cancer are lacking. This work represents one of the first attempts to provide radiation oncologists with quantitative tools to reliably predict the risk of moderate-severe acute GU effects based on both clinical and dosimetric individual parameters," said Dr. Cesare Cozzarini of the San Raffaele Scientific Institute, Dept. of Radiation Oncology in Milan, Italy.

Cozzarini presented the findings at the 5th European Multidisciplinary Meeting on Urological Cancers (EMUC) held in Marseille. A prospective cohort study (DUE-01) which started in April 2010, Cozzarini and colleagues aimed to develop predictive models of genito-urinary (GU) toxicity and erectile dysfunction after high dose radiotherapy (RT) for prostate cancer.

Patients treated with conventional (1.8-2Gy/fr, CONV) or moderate hypo-fractionation (2.5-2.7Gy/fr HYPO) were included.

In their ad-interim analysis, the investigators also intended to find a link between pollakiuria (POLL), dysuria (DYS) and nicturia (NICT) as measured by IPSS at RT end and clinical/dosimetric risk factors.

IPSS questionnaire at the start and at the end of RT were prospectively collected by the researchers and planning data were recovered and analyzed with a dedicated program (Vodca, MSS GmbH, Zurich), including absolute (cc/cm2) and % bladder dose-volume/surface (DVH/DSH) parameters referred to both the whole treatment and to the weekly delivered dose (DVHw/DSHw).

In the study, relevant clinical factors were also prospectively collected including T stage, concomitant morbidities and drugs, use of hormonal therapy (HT), previous surgery, smoking, age, BMI and prostate volume. In IPSS, each item ranges from 0 to 5 with increasing score which indicates increasing toxicity severity: for each question, a score≥4 at the end of the therapy was considered as the end point.

At the time of the analysis (January 2013), 339 patients have been enrolled by nine institutes. Clinical data of 212/339 patients were available (93 CONV and 119 HYPO). Of 172/212 patients both baseline and end-RT IPSS were collected. For 179/212 patients also DVH/DSH were available. Questions POLL, DYS and NICT (respectively 2, 3 and 7) showed the larger increase of the fraction of patients with scores ≥4 between basal and end questionnaire; consequently, the analysis focused on these symptoms.

The number of patients with scores≥4 increased from 8 to 30 for POLL, from 5 to 20 for DYS and from 12 to 34 for NICT. At MVA (overall p<0.0001), the main independent predictors of acute POLL were: Smoking (OR:2.74, p=0.04) and S8.5w (OR:1.01, p=0.10); AUC=0.66. The model was confirmed also after the exclusion of patients with baseline IPSS-POLL ≥4 (AUC=0.69).

"This study (DUE01) is aimed at prospectively collecting an enormous number of patient-reported information concerning GU toxicity (and erectile dysfunction as well) before, during and at the end of radiotherapy and for a period of five years after its completion," said Cozzarini.

"The study therefore has a high probability of helping to develop highly reliable models for the prediction of acute and late GU toxicity and erectile dysfunction and their impact on quality of life," he added.

"As a consequence, the final results of this investigation should have a significant impact on the evolution of radiotherapy of prostate cancer in the next five to 10 years leading to a significant reduction of GU toxicity and sexual dysfunction deriving from a more refined "tailoring" of the radiation therapy," according to Cozzarini.


'/>"/>

Contact: Evgenia Starkova
e.starkova@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Flavor Your Life Shares How to Prepare an Italian Style Orecchiette Pasta with Olive Oil
2. Flavor Your Life Shares 3 Easy Recipes that Use Italian Olive Oil to Enhance Meals
3. Mesothelioma News Update: Resource4thePeople Applauds Italian Court for Sentencing Swiss Millionaire in Asbestos Scandal
4. Springer partners with the Italian Society of Gerontology and Geriatrics
5. First Narconon Cannabis Abuse Prevention Guide Takes Aim at Drug Abuse Statistics for Italian Youth
6. Springer to collaborate with the Italian Society for the Study of Eating Disorders
7. Flavor Your Life Highlights the Importance of Taste in Italian Olive Oil
8. Nationally Renowned Health Expert Debuts Book "Sex and Spaghetti Sauce: My Italian Mother’s Recipe for Getting Healthy and Getting Busy in Your 50s and Beyond"
9. Italian wolves prefer pork to venison
10. KD LUXE Jewelry and Accessories: Introducing Chic Italian Silver and Stainless Collections in Beverly Hills and Hollywood
11. Springer launches new journal with the Italian Association of Nuclear Medicine and Molecular Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: